The Benefits of Palliative Care for People Living with Lung Cancer

Palliative care is supportive care that anticipates, prevents, and treats the symptoms and side effects of the disease and its treatment. It is intended to improve one's quality of life and can be addressed at any stage from diagnosis forward.

This webinar features Estelamari Rodriguez, MD, MPH, thoracic oncologist at the Sylvester Comprehensive Cancer Center at the University of Miami. This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Raise Your Voice: Speaking Up About Living With Lung Cancer

An online panel discussion offers real-world suggestions and examples for ways to get the care and support you need. The discussion features Angela James, LUNGevity care navigator;  Lavern McDonald, a teacher living with lung cancer; and Patricia Simmers, a nurse navigator. The panelists share their personal stories, challenges, and lessons learned through their journeys with lung cancer. This panel discussion was hosted by LUNGevity in collaboration with Novartis.

World Lung Cancer Day and the Changing Landscape of Lung Cancer

For decades, lung cancer was synonymous with low survival rates, limited treatment options, and poor quality of life for those living with the disease. Each year, more than 236,000 people in the US are diagnosed with lung cancer. The high incidence of lung cancer means scientific research into new therapies is critical, both for current survivors and those who will be diagnosed in the future. Thankfully, the landscape of lung cancer is changing for the better.

Facebook Live: A Conversation with the EGFR Resisters Patient Group

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, chats with Jill Feldman and Ivy Elkins, co-founders of the EGFR Resisters; and Drs. Christine Lovly, MD, PhD (Vanderbilt University) and Helena Yu, MD (Memorial Sloan Kettering), who received the 2021 EGFR Resisters/LUNGevity Foundation Awards. Hear first-hand from both patients and researchers about why this patient-driven partnership matters to the EGFR community.